Brainsway (BWAY) Gets a Buy Rating from Oppenheimer
By Austin Angelo
June 24, 2020 Healthcare, Top Market News
Brainsway (BWAY) Gets a Buy Rating from Oppenheimer Oppenheimer analyst Steven Lichtman assigned a Buy rating to Brainsway (BWAY – Research Report) yesterday and set a price target of $13.00. The company’s shares closed last Wednesday at $6.15, close to its 52-week low of $5.10.
According to TipRanks.com, Lichtman is a 1-star analyst with an average return of -2.7% and a 49.7% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Zimmer Biomet Holdings, and Merit Medical Systems.
Brainsway has an analyst consensus of Hold.
Based on Brainsway’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $6.29 million and GAAP net loss of $2.32 million. In comparison, last year the company earned revenue of $4.77 million and had a GAAP net loss of $2.15 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Brainsway Ltd. engages in the research, development and marketing of medical device for non-invasive treatment of the brain disorders. Its technology enables handling of a wide range of indications through the TMS Deep system developed by the company. Brainsway operates through the following segments: Major depression and Obsessive Compulsive Disorder (OCD). The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel. https://www.analystratings.com/articles/brainsway-bway-gets-a-buy-rating-from-oppenheimer/